Absence of Aberrant Plasma Cells in the Apheresis Product Predicts for Minimal Residual Disease Negativity after Autologous Transplantation in Myeloma Patients Who Receive First Line Therapy

Authors :: Ioannis Ntanasis-Stathopoulos
Paraskevi Micheli
Maria Gavriatopoulou
Evangelos Terpos
Efstathios Kastritis
Meletios A. Dimopoulos
Evangelos Eleutherakis-Papaiakovou
Ourania E. Tsitsilonis
Ioannis Kostopoulos
Christine-Ivy Liacos
Magdalini Migkou
Aristea-Maria Papanota
Nikolaos Kanellias
Despina Fotiou
Panagiotis Malandrakis
Source :: Clinical Lymphoma Myeloma and Leukemia. 19:e184-e185
Publication Year :: 2019
Publisher :: Elsevier BV, 2019.

Subjects :: Cancer Research
medicine.medical_specialty
Apheresis
First line therapy
Oncology
business.industry
Product (mathematics)
Medicine
Autologous transplantation
Hematology
Minimal Residual Disease Negativity
business
Surgery

Full Text Access

Tools